Supernus Receives Three Years of Market Exclusivity for Oxtellar XR(TM)

Supernus Receives Three Years of Market Exclusivity for Oxtellar XR(TM)

ROCKVILLE, Md., Nov. 19, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,
Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, announced today that
it has received confirmation from the Food and Drug Administration (the "FDA")
that Oxtellar XR has been granted three years of market exclusivity. Supernus
received approval from the FDA on October 19, 2012 for Oxtellar XR, a novel
once-daily extended release antiepileptic drug indicated for adjunctive
therapy in the treatment of partial seizures in adults and in children 6 to 17
years of age. In addition, Oxtellar XR is currently protected by two issued
U.S. patents that expire no earlier than 2027.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The company has one approved product for
epilepsy, Oxtellar XR™ (extended-release oxcarbazepine), and one tentatively
approved product for epilepsy, Trokendi XR™ (extended-release topiramate). The
company is also developing several product candidates in psychiatry to address
large market opportunities in ADHD including ADHD patients with impulsive
aggression. These product candidates include SPN-810 for impulsive aggression
in ADHD and SPN-812 for ADHD.

CONTACT: Jack Khattar, President & CEO
         Gregory S. Patrick, Vice President and CFO
         Supernus Pharmaceuticals, Inc.
         Tel: (301) 838-2591
 
Press spacebar to pause and continue. Press esc to stop.